Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
C-type lectin domain family 12 member B (CLEC12B) is a membrane-bound inhibitory receptor primarily expressed on myeloid cells. It is characterized by an extracellular C-type lectin-like domain and a cytoplasmic immunoreceptor tyrosine-based inhibition motif (ITIM)[3][1]. Upon activation and phosphorylation, CLEC12B recruits SH2 domain-containing tyrosine phosphatases (SHP-1 and SHP-2), antagonizing activating signals within immune cells and contributing to immune homeostasis and protection of target tissues against natural killer cell-mediated lysis. CLEC12B is involved in processes such as regulation of melanocyte proliferation, inhibition of signal transduction, and modulation of immune cell activation during infection and inflammation. Genetic associations include cone-rod dystrophy 1[1][4][7]. No known direct drug interactions or biomarker uses have been identified for CLEC12B at this time.
Recruitment of phosphatases SHP-1 (PTPN6) and SHP-2 (PTPN11) to its immunoreceptor tyrosine-based inhibition motif (ITIM), resulting in antagonism of activating immune cell signals and downregulation of specific cell activation pathways[1][3][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on C-type lectin domain family 12 member B (CLEC12B).